Beijing Tsingke Biotech Co., Ltd. a gene synthesis company based in Beijing, reportedly raised RMB 400 million (USD 57.5 million) in a Series B financing round. The round was co-led by Henan Investment Group Huirong Fund Management Co., Ltd and Fortune Capital. Other investors included Capitallink, Qingsong Fund, Zhongyuan Asset Management, and Jolmo Investment. Proceeds will go towards research and development (R&D) investment, technology platform upgrade, talent team expansion, and global operation layout.
Company Background and Technology
Founded in 2004, Tsingke Bio’s offerings cover genomics products and services, life science materials and equipment, and biological manufacturing contract organization services. The company, combining the innovative gene intelligent molecular separation and assembly technology with the AI algorithm of the propeller system (TSINGKE HELIXTECH), connects raw materials, equipment, and processes to build an intelligent production line. Through accurate gene detection and quality inspection technology, it has jointly realized low-cost, efficient, and high-quality synthesis services.-Fineline Info & Tech
